3 Ways The COVID-19 Pandemic Is Actually Hurting Some Healthcare Stocks

Brian Orelli, PhD, The Motley Fool
·7-min read

While many healthcare companies are benefiting from the COVID-19 pandemic through the development of vaccines and treatments for the novel coronavirus, others aren't faring nearly as well. In this video from Motley Fool Live recorded on Nov. 30, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com contributor Brian Orelli discuss complications ranging from fewer scheduled surgeries and clinical trial slowdowns to issues with Food and Drug Administration inspections at manufacturing plants. Corinne Cardina: Let's turn now to talk about the effect of the COVID-19 pandemic on some other broad healthcare stocks that might not necessarily be involved in developing coronavirus vaccines or treatments.